MGMT and neoplasm: Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (9.7 months, 95% CI 8.0–11.4) versus 6.8 months (95% CI 5.9–7.7; HR 0.56; 95% CI 0.34–0.93, P = 0.02), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 0.97, 95% CI 0.69–1.38; P = 0.81).